199 related articles for article (PubMed ID: 17585116)
1. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans.
Okudaira T; Kotegawa T; Imai H; Tsutsumi K; Nakano S; Ohashi K
J Clin Pharmacol; 2007 Jul; 47(7):871-6. PubMed ID: 17585116
[TBL] [Abstract][Full Text] [Related]
2. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
Kurnik D; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
[TBL] [Abstract][Full Text] [Related]
3. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
4. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
5. Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
Chung E; Nafziger AN; Kazierad DJ; Bertino JS
Clin Pharmacol Ther; 2006 Apr; 79(4):350-61. PubMed ID: 16580903
[TBL] [Abstract][Full Text] [Related]
6. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Ito K; Ogihara K; Kanamitsu S; Itoh T
Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
[TBL] [Abstract][Full Text] [Related]
8. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam.
Ma JD; Nafziger AN; Rhodes G; Liu S; Bertino JS
Drug Metab Dispos; 2006 May; 34(5):783-5. PubMed ID: 16467135
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
10. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
11. Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers.
Misaka S; Nakamura R; Uchida S; Takeuchi K; Takahashi N; Inui N; Kosuge K; Yamada S; Watanabe H
Clin Ther; 2011 Feb; 33(2):246-52. PubMed ID: 21497708
[TBL] [Abstract][Full Text] [Related]
12. Sex differences in CYP3A activity using intravenous and oral midazolam.
Chen M; Ma L; Drusano GL; Bertino JS; Nafziger AN
Clin Pharmacol Ther; 2006 Nov; 80(5):531-8. PubMed ID: 17112809
[TBL] [Abstract][Full Text] [Related]
13. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.
Zimmermann T; Yeates RA; Laufen H; Scharpf F; Leitold M; Wildfeuer A
Arzneimittelforschung; 1996 Feb; 46(2):213-7. PubMed ID: 8720318
[TBL] [Abstract][Full Text] [Related]
14. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
15. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
Ring BJ; Patterson BE; Mitchell MI; Vandenbranden M; Gillespie J; Bedding AW; Jewell H; Payne CD; Forgue ST; Eckstein J; Wrighton SA; Phillips DL
Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
[TBL] [Abstract][Full Text] [Related]
16. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
Zhang W; Tan TM; Lim LY
Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.
Prueksaritanont T; Vega JM; Rogers JD; Gagliano K; Greenberg HE; Gillen L; Brucker MJ; McLoughlin D; Wong PH; Waldman SA
J Clin Pharmacol; 2000 Nov; 40(11):1274-9. PubMed ID: 11075313
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich V; Murakoso K; Sato H
Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
[TBL] [Abstract][Full Text] [Related]
19. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
[TBL] [Abstract][Full Text] [Related]
20. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis.
Kaneshiro Y; Oda Y; Iwakiri K; Masada T; Iwaki H; Hirota Y; Kondo K; Takaoka K
Clin Pharmacol Ther; 2006 Oct; 80(4):396-402. PubMed ID: 17015057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
